GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2007

Medarex and Organon Ink Biotherapeutics Development Agreement

  • Organon, the human health care business unit of Akzo Nobel, and Medarex will work together to develop and potentially commercialize fully human antibody therapeutics for the treatment of cancer and auto-immune disorders, utilizing Medarex’s UltiMAb Human Antibody Development System® and Organon’s expertise in drug discovery and development.

    Under the terms of the agreement, Medarex and Organon plan to share development and commercialization responsibilities on any antibody-based therapeutics resulting from this collaboration and to share revenues generated from the sale of such therapeutic products.

    “We have recently increased our efforts in Cambridge, Massachusetts, to identify novel biologicals that will be effective treatments for auto-immune and oncological disorders, this additional collaboration with Medarex represents a further step toward becoming an effective biological drug hunting company,” says David Nicholson, executive vp, R&D, at Organon.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?